Abstracts Archive - Page 1041 of 2425 - ACR Meeting Abstracts

Abstract Number: 546 • 2018 ACR/ARHP Annual Meeting
Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis
Peter C. Taylor¹, Yoshiya Tanaka², Anabela Cardoso³, Jinglin Zhong⁴, Yun-Fei Chen³, Jennifer Lynn Workman³, Liliana del Carmen Morales⁵ and Michael Schiff⁶, ¹Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴IQVIA, Morrisville, NC, ⁵INStituto Reumatologica Strusberg, Cordoba, Argentina, ⁶University of Colorado, Greenwood Village, CO
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor approved for the treatment of moderately to severely active RA in adults in over 40 countries including…
Abstract Number: 547 • 2018 ACR/ARHP Annual Meeting
Corticosteroid Bridging Strategies with Methotrexate Monotherapy in Early Rheumatoid and Undifferentiated Arthritis; A Comparison of Efficacy and Toxicity in 2 Clinical Trials
Elisabeth G. Brilman¹, Joy A. van der Pol¹, Pascal HP de Jong^2,3, Angelique EAM Weel^2,3, JMW Hazes², Tom W.J. Huizinga⁴ and Cornelia F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: What is the optimal glucocorticoid (GC) bridging therapy with MTX monotherapy in early arthritis? Methods: In trial A, early RA and UA (arthritis in ≥1…
Abstract Number: 548 • 2018 ACR/ARHP Annual Meeting
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Ying Shan², Tamara Lesperance³, Sabrina Rebello², Elaine Karis⁴, Greg Kricorian⁴, Winnie Hua⁵, Neil A. Accortt⁴ and Scott Stryker⁴, ¹Corrona LLC, Waltham, MA, ²Corrona, LLC, Southborough, MA, ³DOCS Global, Inc., North Wales, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Corrona, LLC, Waltham, MA
Background/Purpose: Monotherapy with etanercept (ETN) may be a viable therapeutic option for maintenance of patients with rheumatoid arthritis (RA) who prefer to eliminate potential burdens…
Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Dimitrios A. Pappas^1,2, Namita Tundia³, Ying Shan², Heather J Litman² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
Abstract Number: 550 • 2018 ACR/ARHP Annual Meeting
Biologic Discontinuation in Rheumatoid Arthritis: A Population Based Study 1999-2017
Michael Richter¹, Eric L. Matteson², John M. Davis III², Sara J. Achenbach³ and Cynthia S. Crowson³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Biologic discontinuation in rheumatoid arthritis: a population based study 1999-2017.Michael D Richter, Eric L Matteson, John M Davis III, Sara J Achenbach, Cynthia S Crowson…
Abstract Number: 551 • 2018 ACR/ARHP Annual Meeting
Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
Gezmis Kimyon¹, Sedat Kiraz², Ihsan Ertenli², Orhan Kucuksahin³, Ediz Dalkiliç⁴, Cemal Bes⁵, Nilufer Alpay Kanitez⁶, Timucin Kasifoglu⁷, Hakan Emmungil⁸, Belkıs Nihan Coşkun⁴, Burcu Yagız⁴, Suleyman Serdar Koca⁹, Muhammet Cinar¹⁰, Aşkın Ateş¹¹, Servet Akar¹², Duygu Ersozlu Bakirli¹³, Veli Yazisiz¹⁴, Nazife Sule Yasar Bilge⁷, Muge Aydin Tufan¹⁵, Ridvan Mercan¹⁶, Omer Karadag², Ayse Bahar Kelesoglu¹¹, Onay Gercik¹⁷, Burak Oz⁹, Zeynel Abidin Akar⁹, Sedat Yılmaz¹⁸, Sezin Turan⁸, Yavuz Pehlivan⁴, Ender Terzioglu¹⁴, Levent Kilic², Sukran Erten¹⁹, Emre Tekgöz¹⁰, Koray Tascilar²⁰ and Umut Kalyoncu², ¹Rheumatology, Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Rheumatology, Liv Hospital, Ankara, Turkey, ⁴Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁵Department of Rheumatology, Health Sciences University Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁶Rheumatology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, ⁷Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey, ⁸Rheumatology, Trakya University Faculty of Medicine, Edirne, Turkey, ⁹Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ¹⁰Rheumatology, Gülhane Military Medical Academy, Faculty of Medicine, Ankara, Turkey, ¹¹Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ¹²Department of Internal Medicine, Division of Rheumatology,, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹³Department of Rheumatology, Adana Numune Training and Research Hospital, Adana, Turkey, ¹⁴Rheumatology, Akdeniz University Faculty of Medicine, Antalya, Turkey, ¹⁵Rheumatology, Baskent University Faculty of Medicine, Adana, Turkey, ¹⁶Rheumatology, Namik Kemal University Faculty of Medicine, Tekirdağ, Turkey, ¹⁷Rheumatology, Izmir Katip Çelebi University Faculty of Medicine, Izmir, Turkey, ¹⁸Division of Rheumatology, Gülhane Military Medical Academy, Faculty of Medicine, Ankara, Turkey, ¹⁹Rheumatology, Yildirim Beyazit University Faculty Of Medicine, Ankara, Turkey, ²⁰Rheumatology, Okmeydani Research and Training Hospital, Istanbul, Turkey
Background/Purpose: Methotrexate and leflunomide are anchor conventional synthetic DMARDs (csDMARDs) for rheumatoid arthritis (RA) treatment. Although methotrexate is the usual recommended concomitant csDMARD along with…
Abstract Number: 552 • 2018 ACR/ARHP Annual Meeting
Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-
Kosuke Ebina¹, Makoto Hirao², Motomu Hashimoto³, Wataru Yamamoto⁴, Akira Onishi⁵, Toru Hirano⁶, Ryota Hara⁷, Masaki Katayama⁸, Shuzo Yoshida⁹, Koji Nagai⁹, Yonsu Son¹⁰, Hideki Amuro¹⁰, Kengo Akashi¹¹, Koichi Murata³, Kosaku Murakami¹², Keiichi Yamamoto¹³ and Hideki Yoshikawa¹⁴, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, ⁷The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan, ⁸Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁹Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan, ¹⁰First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ¹¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ¹²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Department of Medical Statistics, Osaka City University, Osaka, Japan, ¹⁴Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Drug tolerability indicates both the patient’s and doctor’s satisfaction and useful summary measure of overall treatment effectiveness and toxicity. Although more than 5 years…
Abstract Number: 553 • 2018 ACR/ARHP Annual Meeting
Channeling to Treatment and Associated Changes in Disease Activity Over 12 Months in Patients With RA Treated With Abatacept Versus Other DMARDs in Real-World Community Practice Settings
Leticia Ferri¹, Jeffrey R. Curtis², Ying Bao¹, Evo Alemao¹, Tammy Curtice¹, Joshua Bryson¹, Karissa Lozenski¹, Sandhya Balachandar¹ and Varshini Rajagopalan³, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Alabama at Birmingham, Birmingham, AL, ³Mu Sigma, Bangalore, India
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulatory modulator, has shown efficacy similar to TNF inhibitors (TNFi) for RA management in clinical trial settings, but different…
Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting
Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?
Yuki Ishikawa¹, Motomu Hashimoto², Hiromu Ito³, Masao Tanaka², Naoichiro Yukawa⁴, Takao Fujii⁵, Wataru Yamamoto⁶, Tsuneyo Mimori⁷ and Chikashi Terao^8,9,10, ¹One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, ⁵Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, ⁶Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁷Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁸Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, ⁹Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ¹⁰Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…
Abstract Number: 555 • 2018 ACR/ARHP Annual Meeting
Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function
Takahiko Sugihara¹, Tatsuro Ishizaki², Hiroyuki Baba³, Takumi Matsumoto³, Shoko Iga¹, Takeshi Kusuda¹, Marina Tsuchida¹, Mari Kamiya³, Yoji Komiya³, Fumio Hirano⁴, Tadashi Hosoya³, Nobuyuki Miyasaka³ and Masayoshi Harigai⁵, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Department of Rheumatology, Tokyo, Japan, ⁵Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan
Background/Purpose: The aim of this study was to evaluate three year outcomes of patients with elderly-onset RA (EORA) who were treated with a therapeutic strategy…
Abstract Number: 556 • 2018 ACR/ARHP Annual Meeting
Treatment Initiation and Duration in DMARD Naïve Rheumatoid Arthritis Patients: Analysis of US Health Plan Claims
Robin K. Dore¹, Jenya Antonova² and Jerrold Hill³, ¹Univ of California, Los Angeles, CA, ²Gilead Sciences, Foster City, CA, ³Health Economics Outcomes Research, Real World Evidence, IQVIA, Plymouth Meeting, PA
Background/Purpose: The ACR treat-to-target approach for rheumatoid arthritis (RA) recommends regular assessments of disease activity and adjustment of medication regimen until efficacy goals are met.…
Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting
The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study
Axel Finckh¹, Christophe Tellenbach², Almut Scherer², Burkhard Moeller³, Adrian Ciurea⁴, Ines von Mühlenen⁵, Cem Gabay⁶, Diego Kyburz⁷, Ruediger Mueller⁸, Paul Hasler⁹ and Pascal Zufferey¹⁰, ¹University Hospital of Geneva, Geneva, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Rheuma-Basel, Basel, Switzerland, ⁶University Hospitals of Geneva, Geneva, Switzerland, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Kantonsspital Aarau AG, Aarau, Switzerland, ¹⁰Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland
Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
Abstract Number: 558 • 2018 ACR/ARHP Annual Meeting
Major Reduction of Ultrasound Detected Synovitis during Subcutaneous Tocilizumab Treatment; Results from a Multicenter 24 Weeks Study of Patients with Rheumatoid Arthritis
Hilde B Hammer¹, Inger Marie Jensen Hansen², Pentti Järvinen³, Marjatta Leirisalo-Repo⁴, Michael Ziegelasch⁵, Birte Agular⁶ and Lene Terslev⁷, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Svendborg Hospital, Svendborg, Denmark, ³Rheumatology, Kiljava Medical Research, Kiljavan, Finland, ⁴Rheumatology, University of Helsinki, Helsinki, Finland, ⁵Rheumatology, University Hospital, Linköping, Linköping, Sweden, ⁶Roche, Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Ultrasound (US) is sensitive for detection of synovitis (assessed by Grey Scale (GS) and power/color Doppler). Presence of Doppler activity is found to predict…
Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Young Mo Kang², Wan-Hee Yoo³, Paul Emery⁴, Michael E Weinblatt⁵, Edward C. Keystone⁶, Mark C. Genovese⁷, Gihyun Myung⁸, Evelyn Hong⁸, Inyoung Baek⁸ and Jeehoon Ghil⁸, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), ⁴University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…
Abstract Number: 560 • 2018 ACR/ARHP Annual Meeting
Impact of Formulary Copayment Change on Treatment Patterns in Rheumatoid Arthritis Patients on Etanercept
Hafiz Oko-osi¹, Machaon Bonafede², Mahdi Gharaibeh¹, Janna Manjelievskaia², Lorena Lopez-Gonzalez², David H. Collier¹ and Bradley S. Stolshek¹, ¹Amgen Inc., Thousand Oaks, CA, ²IBM Watson Health, Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease that requires long-term treatment to improve or maintain disease activity. Tumor necrosis factor inhibitors (TNFi), a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].